COPLAVIX PILLS 100MG + 75MG

Packaging

28 pieces

Mechanism of action

KOPLAVIKS - antiaggregatory agent.

Prevention of atherothrombotic events in acute coronary syndrome:

- without ST segment elevation (unstable angina or myocardial infarction without a Q wave), including patients who underwent stenting for percutaneous coronary intervention;

- With the rise of the ST segment (acute myocardial infarction) with drug treatment and the possibility of thrombolysis.

Contraindications

Hypersensitivity to any of the active or auxiliary substances of the drug;

Severe liver failure;

Severe renal failure;

Acute abnormal bleeding, such as bleeding from a peptic ulcer or intracranial hemorrhage;

Allergies to NSAIDs and Fernan-Widal syndrome (acetylsalicylic acid intolerance, asthma and nasal polyposis and paranasal sinuses);

Rare hereditary disorders of the tolerance of galactose, lactase deficiency or glucose-galactose malabsorption syndrome;

Pregnancy and lactation period (see the section “Use during pregnancy and lactation”);

Children's age up to 18 years (safety and efficiency of use are not established);

The simultaneous use of Methotrexate in a dose of more than 15 mg per week.

With caution: moderate hepatic impairment, in which predisposition to bleeding is possible (limited clinical experience of use); mild to moderate renal insufficiency (limited clinical experience); injuries, surgical interventions (see the section "Special Instructions"); diseases in which there is a predisposition to the development of bleeding (especially gastrointestinal or intraocular); simultaneous use of other NSAIDs, incl. and selective COX-2 inhibitors; simultaneous use of Warfarin, Heparin, glycoprotein IIb / IIIa inhibitors and thrombolytic agents (see the Interaction and Special Instructions sections); bronchial asthma and allergies in history (increased risk of allergic reactions to acetylsalicylic acid); gout, hyperuricemia (acetylsalicylic acid, including and in low doses, increases the concentration of uric acid in the blood); in patients with a genetically determined decrease in the function of the isoenzyme CYP2C19 (there are literature data indicating that patients with a genetically determined decrease in the function of the isoenzyme CYP2C19 are exposed to less systemic exposure to the active metabolite of Clopidogrel and their anti-aggregation effect is less pronounced,in addition, they may have a higher incidence of cardiovascular complications after myocardial infarction (compared with patients with normal function of an isoenzyme CYP2C19); simultaneous use of methotrexate in a dose of less than 15 mg per week.

Dosage and administration

Inside Adults and elderly people

Coplavix 100/75 mg should be taken daily once a day, regardless of the meal. Coplavix is ​​started after a single loading dose of clopidogrel in combination with Acetylsalicylic acid.

Patients with acute coronary syndrome without ST segment elevation (unstable stenocardia or myocardial infarction without Q wave)

The maximum beneficial effect is observed by the 3rd month of treatment. The course of treatment is up to 1 year.

Patients with acute myocardial infarction with ST segment elevation

Treatment should begin as soon as possible after the onset of symptoms and continue for at least 4 weeks. Patients older than 75 years of age should begin treatment without a loading dose of clopidogrel.

At temperatures not above 25 ° C.